Aarti Drugs Limited Share Price and Company Fundamentals
Last traded: Yesterday at 9:59 AM
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Key Metrics
PE ratio
15.72
PB ratio
2.34
Dividend yield
0.58%
Beta
0.14
Market cap
₹31.75B
Enterprise value
₹37.23B
Company profile
| Industry / Sector | Drug Manufacturers - Specialty & Generic / Healthcare |
|---|---|
| Full time employees | 1284 |
| Website | https://www.aartidrugs.co.in |
| Mailing address | Mahendra Industrial Estate Ground Floor Road No. 29, Plot No. 109-D Sion (East) Mumbai 400 022 India |
| Phone / Fax | 91 22 2401 9025 / 91 22 2407 3462 |
Dividends
Dividend yield
0.58%
Dividend amount
₹2.00
Payout ratio
4.52%
5Y Avg. yield
-%
Aarti Drugs Limited paid ₹2.00 dividend and the ex-dividend date was 09 Feb 2026.The dividend payout ratio is 4.52%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.AARTIDRUGS dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Mar 2026, following are the company executives and directors listed on Aarti Drugs Limited.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Prakash Moreshwar Patil | Chairman, MD & CEO | 78 | |
| Mr. Harshit Manila Savla | Joint MD & Executive Director | 63 | |
| Mr. Adhish Prakash Patil | CFO & COO | 42 | |
| Mr. Rushikesh Vivek Deole | Company Secretary & Compliance Officer | ||
| Mr. Harit Pragji Shah | Whole-Time Director | 62 | |
| Mr. Uday Moreshwar Patil | Whole-Time Director | 62 | |
| Mr. Rashesh Chandrakant Gogri | MD & Executive Director | 51 | |
| Mr. Dhanaji L. Kakade | Vice President of Technical | ||
| Mr. Vishwa Harshit Savla | Managing Director of the Pinnacle Life Science Private Limited |
Profitability and management effectiveness
Profit margin
8.03%
Operating margin
6.16%
Return on assets
-
Return on equity
-
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Aarti Drugs Limited is 31.75B and its enterprise value is 37.23B. The enterprise value to revenue ratio of AARTIDRUGS is 1.48. The enterprise value to EBITDA ratio of AARTIDRUGS is 12.45.
The AARTIDRUGS's stocks Beta value is 0.14 making it 86% less volatile compared to NSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Aarti Drugs Limited (NSE:AARTIDRUGS) Frequently Asked Questions
1. What is Aarti Drugs Limited's Stock Symbol?
Aarti Drugs Limited trades on NSE under the ticker symbol "AARTIDRUGS".
2. What is Aarti Drugs Limited's stock price today?
One share of AARTIDRUGS stock can currently be purchased for approximately ₹347.75.
3. How can I contact Aarti Drugs Limited?
Aarti Drugs Limited's mailing address is Mahendra Industrial Estate Ground Floor Road No. 29, Plot No. 109-D Sion (East) Mumbai 400 022 India. The company can be reached via phone at 91 22 2401 9025.
4. What is Aarti Drugs Limited's official website?
The official website of Aarti Drugs Limited is https://www.aartidrugs.co.in.